Advertisement

Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Immunologic Reactions
  • Danielle Zimmerman
  • Nam Hoang DangEmail author
Reference work entry

Abstract

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immunologic reactions to several stimuli, mostly medications, which present as a spectrum of primarily widespread mucocutaneous lesions, but also with other organ involvement. Pathology is characterized by full thickness necrosis of the epithelial layer of the involved organ due to immune-mediated apoptosis of the resident keratinocytes. High suspicion for early detection and quick withdrawal of the culprit medication are the most important steps in stopping this reaction. Aggressive supportive care is often necessary as the patient recovers. Steroids, other immunosuppressants, and plasmapheresis have all been studied as treatments, but high-quality evidence supporting their contributions, either together or separately, in decreasing length of hospital stay or prolonging survival have not been consistently demonstrated. Further studies of the mechanism of action and novel treatment modalities are still needed to improve outcomes in patients with this rare but often fatal condition.

Keywords

Bullous lesion Mucocutaneous involvement Steroids Stevens–Johnson syndrome Toxic epidermal necrolysis 

References

  1. 1.
    Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162(5):1515–20.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55(4): 496–506.PubMedCrossRefGoogle Scholar
  3. 3.
    Arevalo JM, Lorente JA, González-Herrada C, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma. 2000;48(3): 473–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.PubMedCrossRefGoogle Scholar
  6. 6.
    Blum L, Chosidow O, Rostoker G, Philippon C, Revuz J, Roujeau JC. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol. 1996; 34(6):1088–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Breslin ME, Garcia-Lloret M, Braskett M. A fatal case of drug reaction with eosinophilia and systemic symptoms (DRESS) – Stevens Johnson (SJS)/Toxic epidermal necrolysis (TEN) in the setting of strongyloides infection: treatment considerations. J Allergy Clin Immunol. 2015;135(2):AB124.CrossRefGoogle Scholar
  8. 8.
    Carter FM, Mitchell CK. Toxic epidermal necrolysis – an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum. 1993;36:773.PubMedCrossRefGoogle Scholar
  9. 9.
    Castrejon JL, Berry N, El-Ghaiesh S, Gerber B, Pichler WJ, Naisbitt DJ. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 2010;125(2):411–8.e4.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen ST, Velez NF, Saavedra AP. Adverse cutaneous drug reactions. In: McKean SC, Ross JJ, Dressler DD, Scheurer DB, editors. Principles and practice of hospital medicine, 2e. New York; 2017. Available via ACCESS MEDICINE. http://accessmedicine.mhmedical.com/content.aspx?bookid=1872&sectionid=146980847. Accessed 23 May 2018.
  11. 11.
    Chung WH, Hung SI, Hong HS, Hish MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens Johnson syndrome. Nature. 2004; 428(6982):486.PubMedCrossRefGoogle Scholar
  12. 12.
    Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12): 1343–50.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    de Prost N, Ingen-Housz-Oro S, Duong Ta, Valeyrie-Allanore L, Legrand P, Wolkenstein P, Brochard L, Brun-Buisson C, Roujeau JC. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89(1):28–36.CrossRefGoogle Scholar
  14. 14.
    Dorafshar AH, Dickie SR, Cohn AB, Aycock JK, O’Connor A, Tung A, Gottlieb LJ. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg. 2008;122(1):154–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40(3): 458–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Ellis MW, Oster CN, Turiansky GW, Blanchard JR. A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center. Mil Med. 2002; 167(8):701–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol. 2012; 67(4):630–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6): 1240–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Gaultier F, Rochefort J, Landru MM, Allanore L, Naveau A, Roujeau JC, Gogly B. Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. Arch Dermatol. 2009;145(11):1332–3.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (8th edition) Fitzpatrick’s Dermatology in General Medicine. McGraw Hill, New York. 2012.Google Scholar
  22. 22.
    Gillis NK, Hicks JK, Bell GC, Daily AJ, Kanetsky PA, McLeod HL. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. J Invest Dermatol. 2017; 137(9):2021–3.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Gravante G, Delogu D, Marianetti M, Esposito G, Montone A. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur Rev Med Pharmacol Sci. 2007;11(4):269–74.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2): 157–62.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome at toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Kkezawa Z, Hasegawa R, JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617–22.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Khalaf D, Toema B, Dabbour N, Jehani F. Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011004.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Kinoshita Y, Saeiki H. A review of toxic epidermal necrolysis management in Japan. Allergol Int. 2017; 66(1):36–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Koutlas IG. Diseases of the oral cavity. Clinical dermatology Eds. Carol Soutor, and Maria K. Hordinsky. New York, NY: McGraw-Hill. 2013. http://accessmedicine.mhmedical.com.lp.hscl.ufl.edu/content.aspx?bookid=2184&sectionid=165461482.
  32. 32.
    Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer inhibitory receptors. Clin Exp Immunol. 2000;119(1):225–30.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns. 2010;36(2): 152–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504.PubMedCrossRefGoogle Scholar
  35. 35.
    Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M, RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99–107.PubMedCrossRefGoogle Scholar
  36. 36.
    Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, Lelouet H, Graf E, Schmacher M, Hovnanian A, Mockenhaupt M, Roujeau JC, RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006;6(4):265–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Manuyakorn W, Siripool K, Kamchaisatian W, Pakakasama S, Visudtibhan A, Vilaiyuk S, Rujirawat T, Benjaponpitak S. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatr Allergy Immunol. 2014;24(3):299–303.CrossRefGoogle Scholar
  38. 38.
    McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O’Conner GD, Chalia E, Alhusaini S, Shianna KV, Radtke RA, Keinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91(2):283–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Michel P, Joly P, Ducrotte P, Hemet J, Leblanc I, Lauret P, Lerebours E, Colin R. Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). Dig Dis Sci. 1993;38(10):1938–41.PubMedCrossRefGoogle Scholar
  41. 41.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7:142.PubMedGoogle Scholar
  43. 43.
    Morel E, Escamochero S, Cabanas R, Dias R, Fiandor A, Bellon T. CD94/NKG2R is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2010;125(3):703–10.PubMedCrossRefGoogle Scholar
  44. 44.
    Okamoto-Uchida Y, Nakamura R, Sai K, Imatoh T, Matsunaga K, Aihara M, Saito Y. Effect of infectious disease on the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biol Pharm Bull. 2017;40(9):1576–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Palmieri T, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002; 23(2):87–96.PubMedCrossRefGoogle Scholar
  46. 46.
    Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994; 130(5):605–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE, TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol. 2003;139(1):26–32.PubMedCrossRefGoogle Scholar
  48. 48.
    Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Rosenthal P, Cotter J. The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am. 2003;16(1):89–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–7.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, Schöpf E. Histopathological and epidemiological characteristics of patients with erythema multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2006; 135(1):6–11.CrossRefGoogle Scholar
  52. 52.
    Saito N, Yoshioka N, Abe R, Qiao H, Fujita Y, Hoshina D, Suto A, Kase S, Kitaichi N, Ozaki M, Shimizu H. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. J Allergy Clin Immunol. 2013;131(2):434–41.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33–40.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice – evidence based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149–62.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part 1. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1–13.CrossRefGoogle Scholar
  56. 56.
    Shay E, Kheirkhah A, Liang L, Sheha H, Gregory DG, Tseng SC. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009;54(6):686–96.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, Cheung YK, Zhou JH, Hu XS, Zhou JQ, Zhou LM, Zheng ZZ, Pan J, He N, Liu ZS, Hou YQ, Lim KS, Ou YM, Hui-Ping Khor A, Ng CC, Mao BJ, Liu XR, Li BM, Kuan YY, Yi YH, He XL, Deng XY, Su T, Kwan P, Laio WP. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017;88(23):2183–91.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Shinkai K, Stern RS, Wintroub BU. Cutaneous drug reactions. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, editors. Harrison’s principles of internal medicine, 19e. New York; 2014. Available in ACCESS MEDICINE. http://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79727466. Accessed 23 May 2018.
  59. 59.
    Smith C. Erythema multiforme, Stevens–Johnson syndrome, toxic epidermal necrolysis, staphylococcal scalded skin syndrome. In: Soutor C, Hordinsky MK, editors. Clinical dermatology. New York; 2013. Available via ACCESS MEDICINE. http://accessmedicine.mhmedical.com.lp.hscl.ufl.edu/content.aspx?bookid=2184&sectionid=165460970. Accessed 28 May 2018.
  60. 60.
    Szczeklik W, Nowak I, Seczynska B, Sega A, Krolikowski W, Musial J. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis. Ther Apher Dial. 2010;14(3): 354–7.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, Jantararoungtong T, Koomdee N, Mahakkanukrauh A, Tassaneeyakul W, Suttisai S, Pratoomwun J, Klaewsongkram J, Rerkpattanapipat T, Sukasem C. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429–37.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Valeyrie-Allanore LL, Roujeau J. Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (8th edition). Fitzpatrick’s dermatology in general medicine, McGraw Hill, New York; 2012. Available via ACCESS MEDICINE. http://accessmedicine.mhmedical.com/content.aspx?bookid=392&sectionid=41138737. Accessed 28 May 2018.
  63. 63.
    Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, Bagot M, Roujeau JC. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Williams GP, Mudhar HS, Leyland M. Early pathological features of the cornea in toxic epidermal necrolysis. Br J Ophthalmol. 2007;91(9):1129–32.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Williams R, Hodge J, Ingram W. Indications for intubation and early tracheostomy in patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Surg. 2016;211(4):684–688e1.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Wolff K, Johnson R, Saavedra AP, Roh EK. The acutely ill and hospitalized patient. In: Fitzpatrick’s color atlas and synopsis of clinical dermatology, 8e. New York; 2012. Available via ACCESS MEDICINE. http://accessmedicine.mhmedical.com/content.aspx?bookid=2043&sectionid=154897923. Accessed 23 May 2018.
  67. 67.
    Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140):1586–9.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Wu J, Lee YY, Su SC, Wu TS, Kao KC, Huang CC, Chang WC, Yang CH, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol. 2015;173(5): 1224–31.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Yamane Y, Matsukura S, Watanabe Y, Nakamura K, Kambara T, Ikezawa Z, Aihara M. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients – treatment and outcome. Allergol Int. 2016;65(1):74–81.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid of the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. PLoS One. 2016;11(11):e0167120.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of Florida Health Cancer CenterGainesvilleUSA

Personalised recommendations